BCLI

SEC source: 0001104659-24-049027 · tm2412256-1_4seq1.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 728,493

F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001104659-24-084334 · tm2420560-1_4aseq1.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 728,493

F1 · kind: On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001104659-24-034095 · tm248822-4_4seq1.xml · nonDerivative · entry 1

Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 423,435

F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date.

SEC source: 0001104659-24-034093 · tm248822-3_4seq1.xml · nonDerivative · entry 1

Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,969

F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date.

SEC source: 0001104659-24-034092 · tm248822-2_4seq1.xml · nonDerivative · entry 1

Patlis Alla · CIK 0001639227 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,246

F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date.

SEC source: 0001104659-24-034091 · tm248822-1_4seq1.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 598,493

F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date.

SEC source: 0001104659-23-098326 · tm2325491-1_4seq1.xml · nonDerivative · entry 1

Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001104659-23-087819 · tm2322868-2_4seq1.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 293,295

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-23-088000 · tm2322868-1_4seq1.xml · nonDerivative · entry 1

Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of August 2, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-23-073331 · tm2319343d2_4.xml · nonDerivative · entry 1

Naor Nir · CIK 0001982278 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,999

F1 · shares: Shares acquired are shares of restricted stock awarded on June 19, 2023 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on June 19, 2023 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics Inc. on each vesting date.

SEC source: 0001104659-23-054393 · tm2313994-2_4seq1.xml · derivative · entry 2

Taylor Kirk · CIK 0001975703 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2033-05-01

F2 · derivative.exercise_date: The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on May 1, 2024, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

SEC source: 0001104659-23-054393 · tm2313994-2_4seq1.xml · nonDerivative · entry 1

Taylor Kirk · CIK 0001975703 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The shares of restricted stock will vest in full on May 1, 2024, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.

SEC source: 0001104659-23-048639 · tm2313513-2_4seq1.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,110

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares were fully vested upon grant.

SEC source: 0001104659-23-048632 · tm2313513-1_4seq1.xml · nonDerivative · entry 1

Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares were fully vested upon grant.

SEC source: 0001104659-23-000636 · tm231419-1_4seq1.xml · nonDerivative · entry 1

Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of December 7, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-23-000634 · tm231419-2_4seq1.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,110

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-22-044247 · tm2212273-1_4seq1.xml · derivative · entry 1

FRENKEL JACOB A · CIK 0001237418 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-04-06

F1 · derivative.exercise_date: Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, this option shall vest and become exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2022 until fully vested and exercisable on the 12 month anniversary of April 6, 2022, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-22-033496 · tm228679-1_4seq1.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,310

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-22-011390 · tm225365-1_4seq1.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,960

F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2022 until fully vested on the first anniversary of February 1, 2022, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-21-151218 · tm2135659-5_4seq1.xml · nonDerivative · entry 1

TAUB MALCOLM S · CIK 0001305117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,332

F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.

SEC source: 0001104659-21-151215 · tm2135659-4_4seq1.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,078

F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.

SEC source: 0001104659-21-151214 · tm2135659-3_4seq1.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.

SEC source: 0001104659-21-151211 · tm2135659-2_4seq1.xml · derivative · entry 1

Yablonka Uri · CIK 0001608814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,333

Underlying: Common Stock · 13,333 shares

Expires 2031-12-15

F1 · derivative.exercise_date: Option vests and become exercisable in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested and exercisable on the 12 month anniversary of December 15, 2021.

SEC source: 0001104659-21-151209 · tm2135659-1_4seq1.xml · derivative · entry 1

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,333

Underlying: Common Stock · 25,333 shares

Expires 2031-12-15

F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested and exercisable on the 12 month anniversary of December 15, 2021.

SEC source: 0001104659-21-148754 · tm2135032-9_4.xml · nonDerivative · entry 1

Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,425

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of March 6, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-21-148753 · tm2135032-8_4.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,925

F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-21-148752 · tm2135032-7_4.xml · nonDerivative · entry 1

TAUB MALCOLM S · CIK 0001305117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,332

F1 · shares: Shares acquired are shares of restricted stock awarded effective November 11, 2020 in connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-21-148751 · tm2135032-6_4.xml · nonDerivative · entry 2

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,078

F2 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan . The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-21-148751 · tm2135032-6_4.xml · nonDerivative · entry 1

Polverino Anthony J. · CIK 0001729957 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,078

F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 1, 2021 until fully vested on the first anniversary of February 1, 2021, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-21-148750 · tm2135032-5_4.xml · derivative · entry 1

ARBEL IRIT · CIK 0001245607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,333

Underlying: Common Stock · 25,333 shares

Expires 2031-12-10

F1 · derivative.exercise_date: In connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested and exercisable on the 12 month anniversary of November 11, 2020, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-21-148749 · tm2135032-4_4.xml · derivative · entry 1

FRENKEL JACOB A · CIK 0001237418 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-12-10

F1 · derivative.exercise_date: Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2021 until fully vested and exercisable on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-21-148747 · tm2135032-2_4.xml · derivative · entry 1

Yablonka Uri · CIK 0001608814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,333

Underlying: Common Stock · 13,333 shares

Expires 2031-12-10

F1 · derivative.exercise_date: In connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested and exercisable on the 12 month anniversary of November 11, 2020, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-21-148748 · tm2135032-3_4.xml · nonDerivative · entry 1

Abbhi Sankesh · CIK 0001806887 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,323

F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on the one month anniversary of April 6, 2021 until fully vested on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date.

SEC source: 0001104659-21-148745 · tm2135032-1_4.xml · nonDerivative · entry 1

Almenoff June Sherie · CIK 0001492647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2020 Annual Meeting of Stockholders pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date.

SEC source: 0001104659-20-141128 · tm2039739-1d4.xml · nonDerivative · entry 1

Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,600

F1 · shares: Reflects shares of common stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of a previously reported restricted stock award.

SEC source: 0001104659-20-127446 · tm2036490-1_4.xml · derivative · entry 1

Lindborg Stacy · CIK 0001813667 · EVP, Head Global Clin Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

Underlying: Common Stock · 20,000 shares

Expires 2021-05-21

SEC source: 0001104659-20-103943 · tm2030582d1_4.xml · derivative · entry 2

Waclawski Anthony · CIK 0001823486 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2030-09-08

F2 · derivative.exercise_date: These shares shall vest in full on the one year anniversary of the date of grant.

SEC source: 0001104659-20-103943 · tm2030582d1_4.xml · nonDerivative · entry 1

Waclawski Anthony · CIK 0001823486 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

F1 · shares: Shares acquired are shares of restricted stock awarded effective on September 8, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest in full on July 1, 2021, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-20-089158 · tm2025773d1_4.xml · nonDerivative · entry 1

Lebovits Chaim · CIK 0001406302 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,740

F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2020 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.

SEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 5

ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,053

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.46 to $13.4684, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-084123 · tm2024951-2_4.xml · nonDerivative · entry 1

Setboun David · CIK 0001807545 · EVP and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

SEC source: 0001104659-20-084127 · tm2024951d1_form4.xml · nonDerivative · entry 2

Abbhi Sankesh · CIK 0001806887 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Abbhi Investments, LLC

Disclosed balance after: 2,164,530

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.82 to $13.14, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Abbhi Investments, LLC is the record owner of these securities. Mr. Sankesh Abbhi is the manager of Abbhi Investments, LLC and maintains sole voting and investment power with respect to common stock and warrants held by Abbhi Investments, LLC.

SEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 4

ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,876

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1 to $13.15, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 3

ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,306

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.338 to $13.61, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 2

ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,306

SEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 1

ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,306

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0816 to $13.1581, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-077512 · tm2023245d1_4.xml · nonDerivative · entry 1

Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,543

SEC source: 0001104659-20-068501 · tm2021119-2_4.xml · derivative · entry 2

Lindborg Stacy · CIK 0001813667 · EVP, Head Global Clin Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-06-01

F2 · derivative.exercise_date: The option, awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan, shall vest and become exercisable as to 50,000 of the underlying shares on February 28, 2021 ("First Vesting Date"), and the remaining 50,000 shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter until fully vested and exercisable on the second anniversary of the First Vesting Date, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

SEC source: 0001104659-20-068501 · tm2021119-2_4.xml · nonDerivative · entry 1

Lindborg Stacy · CIK 0001813667 · EVP, Head Global Clin Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Shares acquired are shares of restricted stock awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on December 31, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date.

SEC source: 0001104659-20-044272 · tm2014134d6_4.xml · nonDerivative · entry 1

Setboun David · CIK 0001807545 · EVP and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Shares acquired are shares of restricted stock awarded on April 7, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on the one year anniversary of the date of grant, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date.